Page 109 - Programme book for The International Liver Congress 2015, EASL ILC 2015

Joint Workshop: EASL - JSH Stolz 2

Chairs:
Kazuhiko Koike, Japan
Markus Peck-Radosavljevic, Austria

14:00 Exploring the stemness of hepatocellular carcinoma SCIENTIFIC PROGRAMME
14:20 Taro Yamashita, Japan
14:40
Surveillance, Treatment and Outcome of HCC in Japan
15:00 Masatoshi Kudo, Japan

15:20 Sofosbuvir inhibits hepatitis E virus replcation in vitro and
results in an additive effect when combined with Ribavirin
Jérôme Gouttenoire, Switzerland

Novel meta-analysis of genetic association studies in PBC -
how many risk loci are there?
Pietro Invernizzi, Italy

Discussion and wrap up

Late Breakers Hall D

Chairs:
Massimo Colombo, Italy
Stefan Zeuzem, Germany

ABSTRACT SAFETY OF OMBITASVIR/PARITAPREVIR/RITONAVIR
LO1 PLUS DASABUVIR FOR TREATING HCV GT1 INFECTION
16:00-16:15 IN PATIENTS WITH SEVERE RENAL IMPAIRMENT OR
END-STAGE RENAL DISEASE: THE RUBY-I STUDY
ABSTRACT Paul Pockros, The United States
LO2
16:15-16:30 SIGNIFICANT REDUCTION OF HBSAG AND HDV RNA BY
THE NUCLEIC ACID POLYMER REP 2139 IN CAUCASIAN
ABSTRACT PATIENTS WITH CHRONIC HBV / HDV CO-INFECTION
LO3 Andrew Vaillant, Canada
16:30-16:45
SAFETY AND EFFICACY OF THE COMBINATION
DACLATASVIR-SOFOSBUVIR IN HCV GENOTYPE
1-MONO-INFECTED PATIENTS FROM THE FRENCH
OBSERVATIONAL COHORT ANRS CO22 HEPATHER
Stanislas Pol, France

Vienna, Austria • April 22–26, 2015 109